ABBVIE INC. vs. Xenon Pharmaceuticals Inc
ABBVIE INC. (ABBV) comes out ahead, leading on 4 of 6 compared factors.
Size & Scale
| ABBV | XENE | |
|---|---|---|
| Market Cap | $439.59 billion | $6.31 billion |
| Revenue (TTM) | $64.39 billion | — |
| Net Income (TTM) | $6.32 billion | $-409,195,000 |
ABBV leads on 3 of 3 size & scale factors.
Valuation
| ABBV | XENE | |
|---|---|---|
| P/E Ratio | 70.27 | — |
| Price / Book | -74.66 | 5.08 |
| Price / Sales | 6.83 | — |
ABBV leads on 1 of 1 valuation factors.
Profitability
| ABBV | XENE | |
|---|---|---|
| Net Margin | 9.81% | — |
| Return on Equity | -107.29% | -32.94% |
XENE leads on 1 of 1 profitability factors.
Risk & Sentiment
| ABBV | XENE | |
|---|---|---|
| Short Interest | 0.85% | 0.15% |
XENE leads on 1 of 1 risk & sentiment factors.
Dig deeper: ABBV overview, ABBV financials, XENE overview, XENE financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.